{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:13:23Z","timestamp":1783462403864,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaccao.2022.07.004","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T18:15:32Z","timestamp":1663697732000},"page":"341-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Adam S.","family":"Potter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzamil","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Karimzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaden","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.07.004_bib1","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.07.004_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J. Qual Care Clin Outcomes"},{"key":"10.1016\/j.jaccao.2022.07.004_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0039-3400300","article-title":"Efficacy and safety of nonvitamin k oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis","volume":"120","author":"Cavallari","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaccao.2022.07.004_bib5","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"52","author":"Chan","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jaccao.2022.07.004_bib6","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Deng","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.07.004_bib7","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.07.004_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J","volume":"18","author":"McBane","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaccao.2022.07.004_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib11","first-page":"428","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"Sabatino","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"21","key":"10.1016\/j.jaccao.2022.07.004_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.07.004_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.07.004_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2022.07.004_bib15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2022.07.004_bib16","unstructured":"Parsons LS. Performing a 1:N Case-Control Match on Propensity Score. In: Proceedings of the 29th Annual SAS Users Group International Conference. Cary, North Carolina: SAS Institute."},{"key":"10.1016\/j.jaccao.2022.07.004_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.07.004_bib18","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2012.01.005","article-title":"Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Z\u00f6ller","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2022.07.004_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/154099903768248249","article-title":"Thromboembolic events in the cancer patient","volume":"12","author":"Lin","year":"2003","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.jaccao.2022.07.004_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.07.004_bib21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib25","first-page":"411","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer","volume":"3","author":"Deitelzweig","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.07.004_bib26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.07.004_bib27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.jaccao.2022.07.004_bib28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-glycoprotein transport system and cardiovascular drugs","volume":"61","author":"Wessler","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.07.004_bib29","first-page":"131","article-title":"Use of warfarin in the patient with cancer","volume":"5","author":"Pangilinan","year":"2007","journal-title":"J\u00a0Support Oncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322003192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322003192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:55:13Z","timestamp":1762973713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322003192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666087322003192"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.004","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}